GlassScriptPhysician profile
Catherine M Hegarty
NPI 1295714657
$711.79
in general payments reported to CMS, 2019-2025
14 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $88.07 · 2021: $33.38 · 2022: $44.86 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.42 | 2019-2025 | Evenity |
| Dexcom, INC. | $149.07 | 2025 | Dexcom G7 Gss (161) |
| Radius Health, INC. | $92.86 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $72.56 | 2022-2025 | Eliquis |
| Pfizer INC. | $51.86 | 2019-2020 | |
| Abbott Laboratories | $46.42 | 2019-2020 | |
| Lilly USA, LLC | $27.35 | 2019-2022 | |
| Corcept Therapeutics | $19.48 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.44 | 2019 | |
| Novo Nordisk INC | $16.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.08 | 2019 | |
| Medtronic Minimed, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Hegarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.